Search Results - "Visser, S J de"

Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects by Dumont, G. J. H., De Visser, S. J., Cohen, A. F., Van Gerven, J. M. A.

“…Aims Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also…”
Get full text

Biomarkers for the effects of benzodiazepines in healthy volunteers by De Visser, S. J., Van Der Post, J. P., De Waal, P. P., Cornet, F., Cohen, A. F., Van Gerven, J. M. A.

“…Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be…”
Get full text

The central nervous system effects, pharmacokinetics and safety of the NAALADase‐inhibitor GPI 5693 by Van Der Post, J. P., De Visser, S. J., De Kam, M. L., Woelfler, M., Hilt, D. C., Vornov, J., Burak, E. S., Bortey, E., Slusher, B. S., Limsakun, T., Cohen, A. F., Van Gerven, J. M. A.

“…Aim The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS‐drug target, NAALADase…”
Get full text

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol by Liem-Moolenaar, M., Gray, FA, de Visser, SJ, Franson, KL, Schoemaker, RC, Schmitt, JAJ, Cohen, AF, van Gerven, JMA

“…Central Nervous System (CNS) effects of talnetant, an NK-3 antagonist in development for schizophrenia, were compared to those of haloperidol and placebo. The…”
Get full text

Biomarkers for the effects of antipsychotic drugs in healthy volunteers by De Visser, S. J., Van Der Post, J., Pieters, M. S. M., Cohen, A. F., Van Gerven, J. M. A.

“…Studies of novel antipsychotics in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained…”
Get full text

REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers by Rijnbeek, B., de Visser, S. J., Franson, K. L., Cohen, A. F., van Gerven, J. M. A.

“…The potential use of rapid eye movement (REM) sleep effects as a biomarker for the therapeutic effects of antidepressants in healthy volunteers is reviewed. A…”
Get full text

Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients by van der Post, J. P., de Visser, S. J., Schoemaker, R. C., Cohen, A. F., van Gerven, J. M. A.

“…Previous single-dose studies have shown clear blood pressure-lowering effects of a potential sustained release (SR) profile of rilmenidine, with…”
Get full text

Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE) by de Visser, S.J., Uchida, N., van Vliet-Daskalopoulou, E., Fukazawa, I., van Doorn, M.B.A., van den Heuvel, M.W., Machielsen, C.S.M., Uchida, E., Cohen, A.F.

“…To compare the pharmacokinetic parameters and safety of the progestagen, Org 30659, (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one), and…”
Get full text

Concentration‐effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side‐effects in healthy subjects by De Visser, S. J., Van Gerven, J. M. A., Schoemaker, R. C., Cohen, A. F.

“…Aims  The aim of this study was to compare the effect profiles of i.v. administered rilmenidine aimed at the same target plasma concentration, but attained…”
Get full text

Pharmacodynamics and Pharmacokinetics of a Single Oral Dose of Nitrazepam in Healthy Volunteers: An Interethnic Comparative Study between Japanese and European Volunteers by van Gerven, J. M. A., Uchida, E., Uchida, N., Pieters, M. S. M., Meinders, A. J., Schoemaker, R. C., Nanhekhan, L. V., Kroon, J. M., de Visser, S. J., Altorf, B., Yasuda, K., Yasuhara, H., Cohen, A. F.

“…Potential interethnic differences in drug disposition and effects between Japanese and white subjects hamper the registration in Japan of medications already…”
Get full text

Remnant kenngoor (Phascogale calura) retain genetic connectivity and genetic diversity in a highly fragmented landscape by de Visser, Rhiannon S. J., Hall, Michelle, Ottewell, Kym, Pierson, Jennifer C., Sanders, Angela, Friend, J. Anthony, Berry, Laurence, Hogg, Carolyn, Catullo, Renee A.

“…Kenngoor ( Phascogale calura ) persist in < 1% of their original distribution, occupying highly fragmented remnant habitat in south-west Western Australia,…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S L, de Visser, S J, van der Post, J P, de Smet, M, Schoemaker, R C, Rijnbeek, B, Cohen, A F, Vega, J M, Agrawal, N G B, Goel, T V, Simpson, R C, Pearson, L K, Li, S, Hesney, M, Murphy, M G, van Gerven, J M A

“…TPA023, a GABA(A) alpha2,3 alphasubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., de Smet, M., Schoemaker, R.C., Rijnbeek, B., Cohen, A.F., Vega, J.M., Agrawal, N.G.B., Goel, T.V., Simpson, R.C., Pearson, L.K., Li, S., Hesney, M., Murphy, M.G., van Gerven, J.M.A.

“…TPA023, a GABAA α2,3 αsubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating effects…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., Schoemaker, R.C., van Dyck, K., Murphy, M.G., de Smet, M., Vessey, L.K., Ramakrishnan, R., Xue, L., Cohen, A.F., van Gerven, J.M.A.

“…The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text

Paul Janssen Futurelab Leiden; International Blended Learning Training Program for Entrepreneurial Biomedical Professionals by de Visser, S.J, Kenter, M.J.H, Vingerhoed –van Aken, B

“…Scholarships ZonMw (The Netherlands Organisation for Health Research and Development) funds health research in the Netherlands and promotes the actual use of…”
Get full text

Comparison of Oral and Oral Sustained-Release Rilmenidine in Healthy Volunteers and Correlation with In Vitro Sustained-Release Properties by de Visser, S.J., Vis, P.W., van Gerven, J.M.A., Schoemaker, R.C., Cohen, A.F.

Get full text

Biomarkers for the effects of antipsychotic drugs in healthy volunteers by de Visser, S. J., van der Post, J., Pieters, M. S. M., Cohen, A. F., van Gerven, J. M. A.

Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA alpha2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S L, de Visser, S J, J P van der Post, de Smet, M

“…TPA023, a GABAA alpha2,3 subtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S L, de Visser, S J, van der Post, J P, Schoemaker, R C, van Dyck, K, Murphy, M G, de Smet, M, Vessey, L K, Ramakrishnan, R, Xue, L, Cohen, A F, van Gerven, J M A

“…The use of non-selective gamma-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA^sub A^ [alpha]^sub 2,3^ subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by Haas, S L de, Visser, S J de, Post, J P van der, Schoemaker, R C, Dyck, K van, Murphy, M G, Smet, M de, Vessey, L K, Ramakrishnan, R, Xue, L, Cohen, A F, Gerven, J M A van

“…The use of non-selective y-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text